Skip to main content

Table 1 Baseline characteristics of the patients included in the study (n = 95)

From: Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

VariableN%
Age
  < 70 years old79(83%)
  ≥ 70 years old16(17%)
Comorbidities
 Hypertension13(13,7%)
 Dyslipidemia9(9.5%)
 Diabetes Mellitus3(3.2%)
 Cardiorespiratory disease9(9.5%)
 Liver and renal disease5(5.3%)
 Relevant comorbidity ( grade 2)12(12.6%)
BMI
 BMI < 2543(45%)
 BMI 25–3035(37%)
 BMI > 3017(18%)
Histology
 Infiltrating ductal carcinoma84(88%)
 Infiltrating lobular carcinoma11(12%)
Tumor subtype
 ER and/or PgR positive75(79%)
 Triple Negative16(17%)
 HER2-positive4(4%)
Previous chemotherapies
 Taxane93(98%)
 Capecitabine93(98%)
 Vinorelbine33(35%)
Location of M1
 Bone73(77%)
 Lymph nodes67(71%)
 Liver62(65%)
 Lung29(31%)
 Pleura23(24%)
 Central nervous system20(21%)
 Skin19(20%)
Visceral metastases
 Yes72(76%)
 No23(24%)
Number of organs involved
  ≤ 2 organs35(37%)
  > 2 organs60(63%)
  1. Abbreviations: BMI body mass index, ER estrogen receptor, PgR progesterone receptor